Abstract: TH-PO0767
Spectrum of Primary FSGS in Iraq: Multicentre Cohort Data, 2016-2024
Session Information
- Glomerular Histopathology: Evolving Insights
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Alsaegh, Riyadh Muhi Abbood, University of Kerbala College of Medicine Department of Medicine, Karbala, Iraq
- Allawandi, Ameer H.M., Karbala Health Directorate,Alhusainia General Hospital, Karbala, City Center, Iraq
- Al-Saegh, Ameer Riyadh, Al-Saegh Center for Nephrology and Kidney Transplantation, Karbala, Teachers District, Iraq
- Al-Mukhtar, Maha Abdulrasool, Al-Saegh Center for Nephrology and Kidney Transplantation, Karbala, Teachers District, Iraq
- Al-Saegh, Aya Riyadh, Al-Saegh Center for Nephrology and Kidney Transplantation, Karbala, Teachers District, Iraq
Group or Team Name
- Al-Saegh Research Group.
Background
Focal segmental glomerulosclerosis (FSGS) is a key cause of steroid-resistant nephrotic syndrome in adults, yet regional data are limited.We report Iraqi multicentre data on histology,age, and outcomes.
Methods
We retrospectively reviewed adult native-kidney biopsy reports between January 2014 and December 2024 from three tertiary nephrology units:Imam Al-Hussein Medical City,Al-Saegh Center (Karbala),and Al-Kafeel Center (Najaf). Of 1719 total biopsies,378 were diagnosed with FSGS;126 secondary or inadequate samples were excluded, leaving 252 confirmed primary FSGS cases.Columbia classification was used for histologic subtyping.Descriptive statistics were performed using SPSS v28.Early outcomes were compared to benchmark cohorts from the USA and Korea.
Results
Most FSGS patients were 18–35 y (64.3%),with NOS (75%) as the main variant.Partial remission(PR) was 35.7%, complete remission(CR)21.4%, and ESRD 17.9%.Compared to U.S. and Korea, Iraq showed higher PR,lower ESRD, but lower CR.
Conclusion
Between 2016–2024,primary FSGS in Iraq mainly affected young adults, dominated by NOS/perihilar variants. Despite therapy,1 in 6 progressed to ESRD.Histologic-based treatment and APOL1/genetic screening may improve future precision care.
Table 1:Early renal outcome: current study versus key series
| Study/Region | n | CR% | PR% | ESRD% |
| Current study 2014-2024(Iraq,3 centers) | 252 | 21.4% | 35.7% | 17.9% |
| Thomas 1095 USA | - | 19% | 5% | 23% |
| Koan 2014(Korea) | - | 26.1 | 31.5% | 14.4% |
n :number, CR: complete remission ,PR: partial remission ,ESRD: end stage renal disease.
Age distribution of primary FSGS(2014-2024)
Columbia variants frequencies in Iraqi FSGS cohort.
Funding
- Private Foundation Support